Articles
<![CDATA[Relationship between the general condition of acute lymphoblastic leukemia patients with remission rate and convulsion as an adverse effect chemotherapy ]]>
<![CDATA[Rusdi Andid]]>;
<![CDATA[Nurdiani Nurdiani]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Adi Sutjipto]]>
<![CDATA[ Paediatrica Indonesiana Vol 41 No 1-2 (2001): January 2001 ]]>
Publisher : <![CDATA[Indonesian Pediatric Society ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (367.223 KB)
|
DOI: 10.14238/pi41.1.2001.33-7
<![CDATA[A retrospective study on the relationship between the general condition of acute lymphoblastic leukemia patients with remission rale and convulsion as an adverse effect of chemotherapy was conducted in leukemia patients of the hematology-oncology subdivision, Departmenl of Child Health, Medical School, University of North Sumatra, Medan. Of 114 children with acute lymphoblastic leukemia, 81 (71.05%) received chemotherapy, 31 patients among them was in good general condition. Remission rate of the 31 patients was 80.6% (25 children). Whereas in the remaining 50 patients, the remission rate among them was 84% (42 patients). There was no significant relationship between their general condition to the recurrence rate of acute lymphoblastic leukemia patients who had been administered chemotherapy during induction phase. Convulsion was found In 2 cases, due to CNS leukemia.]]>
<![CDATA[Congenital Malformation Among Newborns at Dr. Pirngadi Hospital Medan During 1981 1984 ]]>
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Guslihan Dasa Tjipta]]>;
<![CDATA[Arman J. O. Panjaitan]]>;
<![CDATA[Noersida Raid]]>;
<![CDATA[Helena Siregar]]>
<![CDATA[ Paediatrica Indonesiana Vol 29 No 1-2 (1989): January - February 1989 ]]>
Publisher : <![CDATA[Indonesian Pediatric Society ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.14238/pi29.1-2.1989.1-7
<![CDATA[A study of the incidence of congenital malformation had been assessed among 15185 newborns delivered in the Neonatal Unit Dr. Pirngadi Hospital Medan during 1981-1984. Still-births were not included in this study.Out of these 15185 newborns there were 77 cases (0.51%) of congenital malformation. The four leading malformations were: pes-equinovarus 7 cases (9. 1 %), labiognathopalatoschizis, hidrocephalus and anencephalus 6 cases each (7.7%).The number of congenital malformation was higher in the age group of mothers older than 35 years (0. 78%) and in the group of babies born in the birth order as third and further (53.85%) and as first born babies (33.33%).From 77 cases with congenital malformation only 2 (2.56%) were operated soon after birth, while 49 cases (64.1%) went home without surgical intervention, and 28 cases (15.9%) died during hospitalization.]]>
<![CDATA[The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients ]]>
<![CDATA[Perjuangan Dapot Hamonangan Simbolon]]>;
<![CDATA[Selvi Nafianti]]>;
<![CDATA[Pertin Sianturi]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Aznan Lelo]]>
<![CDATA[ Paediatrica Indonesiana Vol 58 No 1 (2018): January 2018 ]]>
Publisher : <![CDATA[Indonesian Pediatric Society ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (81.546 KB)
|
DOI: 10.14238/pi58.1.2018.42-7
<![CDATA[Background Chemotherapy-induced nausea and vomiting are some of the most disturbing side effects in pediatric cancer patients. The standard recommendation is the use of 5-hydroxytryptamine 3 receptor antagonist, such as ondansetron, to treat these symptoms. Despite this treatment, more than 50% of patients still experience nausea and vomiting. Objective To evaluate the effect of the addition of omeprazole to ondansetron in the treatment of chemotherapy-induced nausea and vomiting. Methods A double-blind, randomized, controlled trial was conducted at Haji Adam Malik Hospital, Medan, North Sumatera, from March to May 2016. Subjects were children aged 1 to 18 years, diagnosed with cancer, and who received intravenous chemotherapy. Patients were randomized to receive either a single dose of ondansetron (0.5 mg/kg) plus placebo or ondansetron (0.5 mg/kg) plus omeprazole (0.5 mg/kg). The severity of nausea and vomiting were measured using the Rhodes index of nausea, vomiting, and retching during the 24 hours after initiation of emetogenic chemotherapy. The primary outcome of efficacy was the proportion of patients who achieved complete response (lack of nausea/vomiting). Statistical analysis was performed by Chi-square and Fischer’s exact tests. Results Seventy eligible pediatric patients were randomized into two groups: 32 subjects in the ondansetron + placebo group and 38 others in the ondansetron + omeprazole group. The therapy failed in 50% (16/32) of the ondansetron + placebo group and 18.4% (7/38) of the ondansetron + omeprazole group. There was a significant difference in the clinical response between groups (P=0.01). Conclusion The addition of omeprazole to ondansetron for the treatment of chemotherapy-induced nausea and vomiting is more effective than administration of ondansetron alone.]]>
<![CDATA[Immunophenotyping Pattern in Childhood Acute Leukemia in the Adam Malik Hospital Medan ]]>
<![CDATA[Putri Chadijah Tampubolon]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Adi Koesoema Aman]]>;
<![CDATA[Malayana R Nasution]]>
<![CDATA[ INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 27, No 1 (2020) ]]>
Publisher : <![CDATA[Indonesian Association of Clinical Pathologist and Medical laboratory ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.24293/ijcpml.v27i1.1602
<![CDATA[ Leukemia is the most common malignancy at the age of under 15 years, with a ratio of 1 to 3 cancer cases in children.Immunophenotyping will improve accuracy and easily provide data reproducibility. To determine the immunophenotypingpattern in patients with acute leukemia in the Pediatric Center at the Adam Malik General Hospital, Medan. This research wasa cross-sectional study in children suffering from acute leukemia in the Pediatric Unit Adam Malik General Hospital, Medanbased on CBC, peripheral smear, bone marrow morphology, and flow cytometry immunophenotyping. Samples wereevaluated for blast morphologic and immunophenotyping was carried out. Results of morphologic observation andimmunophenotyping were compared. From 20 samples using the monoclonal antibody with flow cytometryimmunophenotyping, concordance with morphology is good (κ = 0.886). After classification, the percentage of acuteleukemia was 45% B-ALL, 35% AML, and 20% T-ALL. One of 10 samples morphologically classified as ALL but reported asAML. Immunophenotyping has been shown to increase diagnostic accuracy and assist in establishing lines in blast cells,which was initially merely based on morphological features.]]>
<![CDATA[THE HEMOGLOBIN, RDW, AND MEAN CORPUSCULAR VALUES IN PATIENTS WITH BETA-THALASSEMIA/HEMOGLOBIN E DISEASE AND BETA-THALASSEMIA TRAIT ]]>
<![CDATA[Vinisia Setiadji]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Adi Koesoema Aman]]>;
<![CDATA[Herman Hariman]]>
<![CDATA[ INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 25, No 3 (2019) ]]>
Publisher : <![CDATA[Indonesian Association of Clinical Pathologist and Medical laboratory ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.24293/ijcpml.v25i3.1459
<![CDATA[Thalassemia beta / hemoglobin E adalah suatu kondisi dengan heterozigot ganda gen pembawa thalassemia beta dan hemoglobin E. Hal ini menyebabkan kondisi dengan gambaran fenotip yang berat dibandingkan trait thalassemia beta dan trait hemoglobin E. Secara logika, nilai mean corpuscular dari thalassemia beta / hemoglobin E seharusnya memburuk. Pada penelitian ini, kami meneliti sebelas kasus dari dua keluarga dengan anggota menderita thalassemia beta / hemoglobin E.Pada keluarga-1 dua anggota dengan trait thalassemia beta memiliki nilai MCV 68 fL dan 65 fL, dan nilai MCH 21 pg dan 20 pg. Pada keluarga-2 anggota dengan trait thalassemia beta memiliki nilai MCV 60,2 fL dan MCH 18,8 pg. Anak perempuan dari kedua keluarga dengan thalassemia beta / hemoglobin E memiliki nilai mean ± SD MCV 70,8 ± 4,9 fL dan MCH 22.8 ± 2.3 pg, nilai ini signifikan lebih tinggi daripada trait thalassemia beta (p<0.05). Terdapat perbedaan yang signifikan antara nilai hemoglobin dan RDW antara thalassemia beta / hemoglobin E (p=0.001).Kami juga menemukan bahwa nilai MC dari keadaan post-transfusi signifikan lebih tinggi daripada pre-transfusi (p<0.001)Kami menyimpulkan bahwa nilai MC dari thalassemia beta / hemoglobin E secara persisten lebih tinggi daripada trait thalassemia beta. Peran transfusi darah pada pasien dengan thalassemia beta / hemoglobin E tampak memainkan peran dalam diskrepansi pada kasus ini.]]>
<![CDATA[Vitamin D, Calcium and Phosphor in Patients with β-Thalassemia Major ]]>
<![CDATA[Ade Hariza Harahap]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Herman Hariman]]>
<![CDATA[ INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 26, No 1 (2019) ]]>
Publisher : <![CDATA[Indonesian Association of Clinical Pathologist and Medical laboratory ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.24293/ijcpml.v26i1.1384
<![CDATA[There has been many reports that patients with β-thalassemia major have bone problems such as thinning of the bone, bone fragility and pathological fractures. For so many years it was believed that the bone problems is mainly caused by marrow expansion due to compenstation of the bone marrow to handle the chronic anaemia and hiypoxia in β-thalassemia major. Recently, there is evidence to suggest that in β-thalassemia major there is hypocalcemia and hypovitaminosis D. So, this study is to clarify if hypovitaminosis D is trully the cause of bone problem in thalassemia. Forty five subjects were recruited in this study, 35 were β-thalassemia major patients and 10 normal subjects as controls. Ten mL of venous blood were taken from median vein for investigations of total vitamin D [25(OH) vitamin D], total calcium and phosphor using the Enzyme-Linked Fluorescent Assay (ELFA), metallochromic dye (Arsenazo III) and chemical reaction of inorganic phosphate with amonium mollybdate respectily. Mean ± SD of vitamin D in β-thalassemia major is 21.28 ± 6.36 ng/ml and in control 34.85 ± 3.50 ng/ml (p<0.05); total calcium in β-thalassemia major is 8.58 ± 0.68 mg/dl and in control 9.22 ± 0.35 mg/dl (p<0.05); and phosphor in β-thalassemia major 3.98 ± 0.53 mg/dl and control 3.89 ± 0.49 mg/dl (p>0.1). There was no significant correlation (r = 0.17, p>0.05), when vitamin D was analysed against calcium for the correlation study,. This study demostrates that there was state of hypovitaminosis D and hypocalcemia in β-thalassemia major but hypovitaminosis D is not the only causative factor of the calcium levels. There should be another factor responsible for the calcium levels in β-thalassemia major and marrow expansion may remain the factors responsible for bone abnomarlities.]]>
<![CDATA[Hubungan antara keracunan timbal dengan anemia defisiensi besi pada anak ]]>
<![CDATA[Bebi Trianita Sari]]>;
<![CDATA[Bidasari Lubis]]>
<![CDATA[ Majalah Kedokteran Nusantara The Journal Of Medical School Vol 47, No 3 (2014): The Journal of Medical School ]]>
Publisher : <![CDATA[Fakultas Kedokteran USU ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (171.478 KB)
<![CDATA[Iron deficiency and lead poisoning often occurs simultaneously causing anemia and showed severe anemia. Conditions of iron deficiency anemia increases the incidence of lead poisoning due to lead and iron have the same receptors that Divalent Metal Transporter 1 (DMT 1). Prevention that children do not suffer from iron deficiency anemia is one way to prevent lead poisoning. In children with BLL above 45 mg / dL, first managed lead poisoning with chelation agents then overcome iron deficiency anemia.Keyword : iron deficiency, lead poisoning, anemia, children]]>
<![CDATA[Perawatan Rongga Mulut pada Pasien Kanker Anak ]]>
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Sisca Silvana]]>
<![CDATA[ Indonesian Journal of Cancer Vol 1, No 4 (2007): Oct - Dec 2007 ]]>
Publisher : <![CDATA[National Cancer Center - Dharmais Cancer Hospital ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (1298.803 KB)
|
DOI: 10.33371/ijoc.v1i4.29
<![CDATA[Pasien anak yang menjalani kemoterapi dapat mengalami berbagai macam komplikasi. Salah satu diantaranya adalah gangguan pada rongga mulut, seperti mukositis, stomatitis, dan infeksi. Hal ini diakibatkan oleh efek samping dan menurunnya daya tahan tubuh anak akibat kemoterapi dan kurang pedulinya orangtua pasien dalam menjaga kebersihan rongga mulut anak. Dokter sebaiknya melakukan penilaian terhadap keadaan di sekitar rongga mulut sebelum anak menjalani kemoterapi. Penilaian ini dapat menunjukkan area yang berpotensi untuk terjadinya infeksi pada rongga mulut. Perawatan rongga mulut dapat dilakukan dengan cara sederhana, seperti rajin menggosok gigi dan berkumur.Kata kunci: perawatan rongga mulut, kemoterapi, kanker anak]]>
<![CDATA[Vitamin D, Calcium and Phosphor in Patients with β-Thalassemia Major ]]>
<![CDATA[Ade Hariza Harahap]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Herman Hariman]]>
<![CDATA[ INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 26 No. 1 (2019) ]]>
Publisher : <![CDATA[Indonesian Association of Clinical Pathologist and Medical laboratory ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.24293/ijcpml.v26i1.1384
<![CDATA[There has been many reports that patients with β-thalassemia major have bone problems such as thinning of the bone, bone fragility and pathological fractures. For so many years it was believed that the bone problems is mainly caused by marrow expansion due to compenstation of the bone marrow to handle the chronic anaemia and hiypoxia in β-thalassemia major. Recently, there is evidence to suggest that in β-thalassemia major there is hypocalcemia and hypovitaminosis D. So, this study is to clarify if hypovitaminosis D is trully the cause of bone problem in thalassemia. Forty five subjects were recruited in this study, 35 were β-thalassemia major patients and 10 normal subjects as controls. Ten mL of venous blood were taken from median vein for investigations of total vitamin D [25(OH) vitamin D], total calcium and phosphor using the Enzyme-Linked Fluorescent Assay (ELFA), metallochromic dye (Arsenazo III) and chemical reaction of inorganic phosphate with amonium mollybdate respectily. Mean ± SD of vitamin D in β-thalassemia major is 21.28 ± 6.36 ng/ml and in control 34.85 ± 3.50 ng/ml (p<0.05); total calcium in β-thalassemia major is 8.58 ± 0.68 mg/dl and in control 9.22 ± 0.35 mg/dl (p<0.05); and phosphor in β-thalassemia major 3.98 ± 0.53 mg/dl and control 3.89 ± 0.49 mg/dl (p>0.1). There was no significant correlation (r = 0.17, p>0.05), when vitamin D was analysed against calcium for the correlation study,. This study demostrates that there was state of hypovitaminosis D and hypocalcemia in β-thalassemia major but hypovitaminosis D is not the only causative factor of the calcium levels. There should be another factor responsible for the calcium levels in β-thalassemia major and marrow expansion may remain the factors responsible for bone abnomarlities.]]>
<![CDATA[THE HEMOGLOBIN, RDW, AND MEAN CORPUSCULAR VALUES IN PATIENTS WITH BETA-THALASSEMIA/HEMOGLOBIN E DISEASE AND BETA-THALASSEMIA TRAIT ]]>
<![CDATA[Vinisia Setiadji]]>;
<![CDATA[Bidasari Lubis]]>;
<![CDATA[Adi Koesoema Aman]]>;
<![CDATA[Herman Hariman]]>
<![CDATA[ INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 25 No. 3 (2019) ]]>
Publisher : <![CDATA[Indonesian Association of Clinical Pathologist and Medical laboratory ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.24293/ijcpml.v25i3.1459
<![CDATA[Beta-thalassemia/hemoglobin E disease is a condition where there is double heterozygosity of beta-thalassemia trait and hemoglobin E trait. This produces a condition with more severe phenotypic appearance compared to beta thalassemia trait and hemoglobin E trait. Logically the Mean Corpuscular Values (MCV) of beta-thalassemia/hemoglobin E disease should also be worsened. The aim of this study was to assess the hemoglobin level, RDW, and MCV between beta-thalassemia/hemoglobin E disease and beta thalassemia trait. The researchers hereby studied eleven cases from two families who were detected to have beta-thalassemia/hemoglobin E disease. Family-1 with beta-thalassemia trait had MCV 68 fL and 65 fL, the MCH value was 21 pg and 20 pg, respectively. In Family-2, mother with beta-thalassemia trait, had MCV 60.2 fL and MCH 18. 8 pg. Daughters with beta-thalassemia/hemoglobin E disease from subjects 1 and 2 whose blood were taken repetitively during visits to the hematology clinic, had mean±SD of MCV 70.8±4.9 fL and Mean Corpuscular Hemoglobin (MCH) value 22.8±2.3 pg. They were significantly higher than the ones with beta-thalassemia trait (p<0.05). Moreover, there were found that the MCV from post-transfusion state were significantly higher than the pre-transfusion state (p<0.001). Based on the study, it could concluded that the MCV from subjects with beta-thalassemia/hemoglobin E disease were persistently higher than the beta-thalassemia trait. The role of blood transfusion in patients with beta-thalassemia/hemoglobin E disease seems to play a part in the result of a discrepancy in this matter.]]>
